Latest News
Researchers have uncovered three new genes that are linked to the possibility of developing Alzheimer’s disease; potentially unlocking new treatment possibilities for patients.
Novartis and Amgen have announced that Aimovig™ has been approved by the US FDA for the preventive treatment of migraine in adults.
A recent trial has determined that moderate-to-high intensity exercise does not slow cognitive decline in individuals with dementia.
Journal Articles
In this research article from Journal of Comparative Effectiveness Research, a new network meta-analysis compares lurasidone and brexpiprazole in acute schizophrenia.
In this research article from Pain Management, researchers investigate the effects of pregabalin, gabapentin and gastroretentive gabapentin on simulated driving performance.
This research article from Neurodegenerative Disease Management investigates how age and disease duration affects Parkinson’s treatment outcome with levodopa-carbidopa intestinal gel.
Autoimmune
Could hyaluronic acid contribute to chronic white matter injury?
Can living in a sunnier climate in your youth reduce the risk of MS?
Cerebrovascular disease
International Nurses Day: a day in the life of Lynn Hundley
International Nurses Day: a day in the life of Ismalia de Sousa
Novartis to seek US approval of siponimod for SPMS: industry news round up
CNS/PNS/SNS
Reprogrammed neuronal stem cells survive long-term in spinal cord injury model
AAN 2018: Investigational drug offers hope for spinal muscular atrophy
New pathways identified in restricting CNS axonal regeneration
Cognitive/neurodegenerative disorders
UK Biobank: new genetic risk factors for Alzheimer’s disease identified
Dementia exercise programs may not slow cognitive decline, study indicates
Multiple sclerosis: new UK guidelines on disease-modifying therapies
Demyelinating disease
Multiple sclerosis: new UK guidelines on disease-modifying therapies
First disease-modifying therapy approved for pediatric multiple sclerosis: industry news round-up
Could hyaluronic acid contribute to chronic white matter injury?
Development and pediatrics
NCTalks with Giovanni Baranello: spinal muscular atrophy and the FIREFISH trial
Possible biomarker for autism identified in cerebrospinal fluid
AAN 2018: Investigational drug offers hope for spinal muscular atrophy
Epilepsy and seizure
Epilepsy and cannabinoids: current consensus, controversies and future outlook
Reports of brain damage call a halt to Bellicum trials: industry news round-up
Could novel epileptic encephalopathy genes promote advances in treatment strategy?
Genetics
UK Biobank: new genetic risk factors for Alzheimer’s disease identified
New pathways identified in restricting CNS axonal regeneration
Novartis to seek US approval of siponimod for SPMS: industry news round up
Headache
Aimovig™ gains US FDA approval for the preventive treatment of migraine
AAN 2018: Novel therapy for ‘difficult-to-treat’ migraines revealed
Immune disorders and inflammation
Could hyaluronic acid contribute to chronic white matter injury?
NCTalks at SfN17: Doris Doudet on Parkinson's, inflammation and the gut
Infection
NCTalks at SfN17: Kijun Yoon gives a Zika update
Injury/trauma
Reprogrammed neuronal stem cells survive long-term in spinal cord injury model
Study indicates all degrees of concussion may increase the risk of Parkinson’s disease
Is there a link between traumatic brain injury and dementia?
Movement disorders
Multiple sclerosis: new UK guidelines on disease-modifying therapies
AAN 2018: Nerve stimulation device may help relieve essential tremors in the hand
Study indicates all degrees of concussion may increase the risk of Parkinson’s disease
Neuro-ophthalmology
Vision in Alzheimer's disease: a focus on the anterior afferent pathway
Glaucoma research gives a glimpse of a novel neuroprotection mechanism
Neurometabolic
Epigenetics, opioids and immune regulation: interviews from SfN17
Jeffrey Iliff: glymphatics, Alzheimer’s and future directions
SfN17: Neurodegeneration and the microbiome – new research highlights
Neuromuscular
New genetic suspects identified for ALS and FTD
Novel discovery in motor neuron disease may pave the way for future treatments
EAN 2017: Guillain-Barré syndrome risk associated with month of birth
Neuropsychiatry
Possible biomarker for autism identified in cerebrospinal fluid
Oncology/tumor
First disease-modifying therapy approved for pediatric multiple sclerosis: industry news round-up
Pain
Aimovig™ gains US FDA approval for the preventive treatment of migraine
Sleep
#NCIntroduces... Sleep science
Better sleep works like a dream at reducing fear learning
Sleep research realizes the dream of understanding brain plasticity mechanisms
